Genentech, a member of the Roche Group announced new Ocrevus (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS)...
Genentech,, announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that...
Genentech, a member of the Roche Group announced late-breaking data from the Phase III OCARINA II study.
The National Institute for Health and Care Excellence (NICE) finalized its decision not to recommend coverage of Roche's Ocrevus (ocrelizumab)...
Genentech, a member of the Roche Group announced that the Phase III OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS (RMS or PPMS)
Genentech/Roche announced a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial specifically to support African-American and Hispanic- and Latin-American patients with MS.
-Genentech has announced that new Ocrevus (ocrelizumab) data will be presented at the 4th Congress of the European Academy of...
Genentech/Roche announced new Ocrevus (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing.
Genentech, a member of the Roche Group announced that new Ocrevus (ocrelizumab) data will be presented at the 34th Congress...
Genentech/Roche announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of Ocrevus (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of a shorter two-hour infusion in minority populations.